Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial-Reference-Cited by-同舟云学术

Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

Published:2014-05-05 Issue:1 Volume:15 Page:
ISSN:1471-2369
Container-title:BMC Nephrology
language:en
Short-container-title:BMC Nephrol

Author:

Ureña-Torres Pablo,Prié Dominique,Keddad Karim,Preston Peter,Wilde Paul,Wan Hong,Copley J Brian

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/content/pdf/10.1186/1471-2369-15-71.pdf

Reference32 articles.

1. Berndt TJ, Schiavi S, Kumar R: “Phosphatonins” and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol. 2005, 289: F1170-F1182. 10.1152/ajprenal.00072.2005.

2. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007, 18: 2600-2608. 10.1681/ASN.2006080936.

3. Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T, Ishimura E, Nishizawa Y: Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006, 17: 1506-1513. 10.1007/s00198-006-0154-6.

4. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, DeFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009, 119: 2545-2552. 10.1161/CIRCULATIONAHA.108.844506.

5. Gutierrez OM, Wolf M, Taylor EN: Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011, 6: 2871-2878. 10.2215/CJN.02740311.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal study to find the association of serum phosphorus level with FGF23 in three different hyperphosphatemia management groups of stage 3 and 4 chronic kidney disease (CKD) patients;Indian Journal of Nephrology;2022

2. Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD;Journal of the American Society of Nephrology;2021-10-13

3. Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis;International Urology and Nephrology;2021-04-02

4. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective;American Journal of Kidney Diseases;2021-01

5. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials;Annals of Palliative Medicine;2021-01